Announcements Trials

Browse Landscape

Status

Not yet recruiting 1

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Advanced or Metastatic Solid Tumors 3 Solid Tumors 2 Sarcoma 2 Carcinoma, Non-Small-Cell Lung 2 Biliary Tract Neoplasms 2 Solid Tumor 1 Histiocytoma, Malignant Fibrous 1 Endometrial Neoplasms 1 Diabetes Mellitus, Insulin-Dependent, 12 1 Dermatofibrosarcoma 1 Colorectal Neoplasms 1 Chondrosarcoma 1 Carcinoma, Renal Cell 1 Carcinoma, Hepatocellular 1 Advanced Solid Tumor 1

Interventions

Injections 24 pembrolizumab 13 toripalimab 12 tislelizumab 9 Gemcitabine 7 Cisplatin 7 Carboplatin 6 atezolizumab 5 Nivolumab 5 Irinotecan 5 Pemetrexed 4 Oxaliplatin 4 Leucovorin 4 Fluorouracil 4 Docetaxel 4 Cetuximab 4 trastuzumab deruxtecan 3 spartalizumab 3 cediranib 3 Paclitaxel 3 PM 01183 3 Capecitabine 3 sintilimab 2 olaparib 2 lenvatinib 2 glumetinib 2 camrelizumab 2 apatinib 2 Therapeutics 2 Midazolam 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Advanced Solid Tumor × envafolimab × Clear all

NCT07562347 2026-05-01

ENCOMPASS STUD

IR INNOVATE RESEARCH PRIVATE LIMITED

Not yet recruiting

Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡